CLOs on the Move

Cowden Associates

www.cowdenassociates.com

 
Cowden Associates is a Pittsburgh, PA-based company in the Business Services sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Homer Miller Company

Homer Miller Company is a Oklahoma City, OK-based company in the Business Services sector.

AandA Merchandising

A&A Merchandising Ltd. is a Etobicoke, ON-based company in the Business Services sector.

M J Engnring Land Surveying PC

M J Engnring Land Surveying PC is a Clifton Park, NY-based company in the Business Services sector.

Jacuzzi Group

Jacuzzi Group is a leading name in hydrotherapy and wellness products, renowned for its innovative whirlpool baths. Founded in 1915 by the Jacuzzi brothers, the company shifted its focus to hydrotherapy in the late 1940s with the development of the J-300 portable hydrotherapy pump. This marked the start of its specialization in therapeutic water-based solutions. The company offers a range of products, including whirlpool baths, portable hydrotherapy pumps, spa and hot tub solutions, and swimming pool equipment. Jacuzzi serves both residential and commercial markets, providing wellness amenities for luxury hotels and rehabilitation centers. With a legacy of innovation and a commitment to premium hydrotherapy products, Jacuzzi Group continues to be a trusted name in over 100 countries.

Alkeus Pharmaceuticals, Inc.

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.